Guidelines from Experts on the Strategic Use of Isotretinoin for Optimal Acne Management: Recommendations from the ERAISE ACNE Consensus - Summary - MDSpire
Advertisement
Guidelines from Experts on the Strategic Use of Isotretinoin for Optimal Acne Management: Recommendations from the ERAISE ACNE Consensus
To develop consensus-based recommendations for the optimal use of oral isotretinoin in acne vulgaris management specifically tailored to the Indian context.
Approach:
Key Findings:
Isotretinoin is recommended as first-line therapy for severe conglobate, nodulocystic, and severe papulopustular acne, with detailed criteria for each type.
Early initiation of isotretinoin after first-line therapy failure is endorsed to prevent progression, scarring, and postinflammatory hyperpigmentation.
Conventional dosing (0.5–1 mg/kg/day) is preferred for severe cases, while low-dose regimens are acceptable for moderate cases, with specific guidelines on duration.
Risk-adapted laboratory monitoring is emphasized over universal approaches, detailing the types of tests recommended.
Procedures like comedone extraction and chemical peels can be used during isotretinoin therapy, with guidelines on patient selection.
Interpretation:
The consensus provides a structured approach to isotretinoin use, addressing regional clinical practices. It emphasizes the importance of early intervention and tailored monitoring to optimize treatment outcomes.
Limitations:
The consensus may not be applicable outside the Indian context or in regions with different patient demographics, which could limit its generalizability.
The study was not prospectively registered, which may affect the perceived rigor of the methodology and the reliability of the findings.
Conclusion:
The ERAISE ACNE consensus offers practical, evidence-based recommendations for isotretinoin use in acne management, aiming to improve patient outcomes and standardize treatment practices across India.
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
